Labcorp Declares Cash Dividend of $0.72 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy LH?
Source: PRnewswire
- Dividend Declaration: Labcorp's Board of Directors has declared a cash dividend of $0.72 per share of common stock, aimed at rewarding shareholders and boosting investor confidence, with payment scheduled for June 11, 2026, to shareholders of record as of May 29, 2026.
- Global Service Network: Labcorp operates in nearly 100 countries, providing innovative and comprehensive laboratory services that help doctors, hospitals, and pharmaceutical companies make informed decisions, highlighting its significant role in the global healthcare landscape.
- Employee Scale and Testing Volume: The company employs nearly 71,000 people and supported over 85% of FDA approvals for new drugs and therapeutic products in 2025, while conducting over 750 million tests for patients worldwide, showcasing its strong market influence and service capabilities.
- Advancing Science and Health: Labcorp is committed to improving health and quality of life through its unparalleled diagnostics and drug development laboratory capabilities, further solidifying its leadership position in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 269.170
Low
270.00
Averages
304.45
High
325.00
Current: 269.170
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp Holdings Declares $0.72 Quarterly Dividend, Consistent with Previous Payout
- Quarterly Dividend Announcement: Labcorp Holdings has declared a quarterly dividend of $0.72 per share, consistent with previous payouts, indicating the company's stable cash flow and profitability, which is likely to attract more income-focused investors.
- Dividend Yield: The forward yield of 1.05% reflects the company's attractiveness in the current market environment, potentially increasing investor interest in its stock.
- Shareholder Timeline: The dividend is payable on June 11, with a record date of May 29 and an ex-dividend date also on May 29, ensuring shareholders receive their returns promptly, thereby boosting shareholder confidence.
- Future Growth Outlook: Labcorp anticipates a 5.4% midpoint revenue growth and a 9% EPS target for 2026, demonstrating the company's strategic commitment to advancing specialty and AI initiatives, which may further enhance its competitive position in the market.
See More
Labcorp Declares Cash Dividend of $0.72 per Share
- Dividend Declaration: Labcorp's Board of Directors has declared a cash dividend of $0.72 per share of common stock, aimed at rewarding shareholders and boosting investor confidence, with payment scheduled for June 11, 2026, to shareholders of record as of May 29, 2026.
- Global Service Network: Labcorp operates in nearly 100 countries, providing innovative and comprehensive laboratory services that help doctors, hospitals, and pharmaceutical companies make informed decisions, highlighting its significant role in the global healthcare landscape.
- Employee Scale and Testing Volume: The company employs nearly 71,000 people and supported over 85% of FDA approvals for new drugs and therapeutic products in 2025, while conducting over 750 million tests for patients worldwide, showcasing its strong market influence and service capabilities.
- Advancing Science and Health: Labcorp is committed to improving health and quality of life through its unparalleled diagnostics and drug development laboratory capabilities, further solidifying its leadership position in the industry.
See More
Labcorp to Release Q1 2026 Financial Results on April 30
- Earnings Release Schedule: Labcorp is set to announce its Q1 2026 financial results before the market opens on April 30, 2026, reflecting the company's ongoing leadership in innovative laboratory services.
- Webcast Discussion: The company will host a webcast at 9:00 a.m. ET on the same day to discuss the financial results, enhancing transparency and investor confidence in the company's performance.
- Investor Relations Information: The earnings press release and accompanying financial information will be posted in the 'News & Events' section of Labcorp's investor relations website, facilitating easy access for investors to the latest updates.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event on the investor relations website for one year, ensuring investors can access important information at their convenience.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration to advance precision oncology using next-generation sequencing (NGS) solutions, expected to promote equitable access to cancer biomarker testing and enhance patient convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic (IVD) tests, aiming to bridge gaps in precision oncology and drive advancements in personalized cancer care.
- Liquid and Tissue Biopsy Integration: The collaboration will explore co-commercializing Labcorp's FDA-authorized liquid biopsy PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, aiming to provide broader biomarker testing for hospitals and community health systems.
- Clinical Utility Research: In a joint study, Illumina's CGP detected variants in over 72% of more than 7,600 non-small cell lung cancer samples that had current targeted therapies or clinical trials, demonstrating CGP's effectiveness in identifying tumor genomic features.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
Labcorp Holdings Declares $0.72 Quarterly Dividend, Consistent with Previous Payout
- Quarterly Dividend Announcement: Labcorp Holdings has declared a quarterly dividend of $0.72 per share, consistent with previous payouts, indicating the company's stable cash flow and profitability, which is likely to attract more income-focused investors.
- Dividend Yield: The forward yield of 1.05% reflects the company's attractiveness in the current market environment, potentially increasing investor interest in its stock.
- Shareholder Timeline: The dividend is payable on June 11, with a record date of May 29 and an ex-dividend date also on May 29, ensuring shareholders receive their returns promptly, thereby boosting shareholder confidence.
- Future Growth Outlook: Labcorp anticipates a 5.4% midpoint revenue growth and a 9% EPS target for 2026, demonstrating the company's strategic commitment to advancing specialty and AI initiatives, which may further enhance its competitive position in the market.
See More
Labcorp Declares Cash Dividend of $0.72 per Share
- Dividend Declaration: Labcorp's Board of Directors has declared a cash dividend of $0.72 per share of common stock, aimed at rewarding shareholders and boosting investor confidence, with payment scheduled for June 11, 2026, to shareholders of record as of May 29, 2026.
- Global Service Network: Labcorp operates in nearly 100 countries, providing innovative and comprehensive laboratory services that help doctors, hospitals, and pharmaceutical companies make informed decisions, highlighting its significant role in the global healthcare landscape.
- Employee Scale and Testing Volume: The company employs nearly 71,000 people and supported over 85% of FDA approvals for new drugs and therapeutic products in 2025, while conducting over 750 million tests for patients worldwide, showcasing its strong market influence and service capabilities.
- Advancing Science and Health: Labcorp is committed to improving health and quality of life through its unparalleled diagnostics and drug development laboratory capabilities, further solidifying its leadership position in the industry.
See More
Labcorp to Release Q1 2026 Financial Results on April 30
- Earnings Release Schedule: Labcorp is set to announce its Q1 2026 financial results before the market opens on April 30, 2026, reflecting the company's ongoing leadership in innovative laboratory services.
- Webcast Discussion: The company will host a webcast at 9:00 a.m. ET on the same day to discuss the financial results, enhancing transparency and investor confidence in the company's performance.
- Investor Relations Information: The earnings press release and accompanying financial information will be posted in the 'News & Events' section of Labcorp's investor relations website, facilitating easy access for investors to the latest updates.
- Replay Availability: A replay of the webcast will be available approximately two hours after the live event on the investor relations website for one year, ensuring investors can access important information at their convenience.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration to advance precision oncology using next-generation sequencing (NGS) solutions, expected to promote equitable access to cancer biomarker testing and enhance patient convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic (IVD) tests, aiming to bridge gaps in precision oncology and drive advancements in personalized cancer care.
- Liquid and Tissue Biopsy Integration: The collaboration will explore co-commercializing Labcorp's FDA-authorized liquid biopsy PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, aiming to provide broader biomarker testing for hospitals and community health systems.
- Clinical Utility Research: In a joint study, Illumina's CGP detected variants in over 72% of more than 7,600 non-small cell lung cancer samples that had current targeted therapies or clinical trials, demonstrating CGP's effectiveness in identifying tumor genomic features.
See More
Illumina and Labcorp Expand Precision Oncology Collaboration
- Collaboration Deepening: Illumina and Labcorp announced an expanded collaboration aimed at enhancing precision oncology through next-generation sequencing solutions, with expectations to promote equitable access to cancer biomarker testing, thereby improving patient testing convenience.
- New Test Development: The companies will jointly develop tests addressing unmet needs, covering advanced oncology research and in vitro diagnostic tests, aiming to bridge existing gaps in precision oncology and improve patient treatment outcomes.
- Co-Commercialization: Plans include co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive, intended to provide broader access to both tissue and liquid biopsy testing for hospitals and community health systems.
- Clinical Utility Research: The companies will continue joint efforts to demonstrate the clinical utility of CGP, with studies showing that CGP detected variants in over 72% of non-small cell lung cancer patient tumors that are relevant to current targeted therapies or clinical trials, further advancing the application of precision medicine.
See More
Middleby Appoints Glenn Eisenberg to Board of Directors
- Board Expansion: The Middleby Corporation announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1, increasing the board to twelve members, which underscores the company's commitment to strategic transformation.
- Extensive Financial Experience: Eisenberg brings a 20-year track record as a public company CFO and senior operating executive, having previously served as CFO at Labcorp, overseeing financial operations in over 100 countries, which is expected to significantly support Middleby's operational initiatives.
- Strategic Focus: Middleby CEO Tim FitzGerald noted that Eisenberg's expertise in financial discipline and capital allocation will be crucial for driving sustainable organic growth, reflecting the company's emphasis on enhancing board capabilities.
- Diverse Leadership Background: Eisenberg currently serves on the boards of two other public companies and has extensive public company governance experience, which will provide valuable oversight for Middleby as it aims to achieve long-term value creation and operational excellence.
See More
